NovoCure (NVCR) Projected to Post Earnings on Thursday

Key Points

• NovoCure is expected to report Q3 2026 results before the market opens on October 29. Analysts forecast a loss of $0.2349 per share and revenue of $182.28 million.
• The company exceeded expectations in its prior quarter, posting a $0.13-per-share loss versus the expected $0.33 loss, while revenue rose 15.6% year over year to $183.58 million.
• Analysts maintain a generally neutral view of NVCR. The stock has an average “Hold” rating and a $21.20 price target, compared with its recent price of $15.59.

NovoCure (NASDAQ:NVCR - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.2349) per share and revenue of $182.28 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.20. NovoCure had a negative return on equity of 44.00% and a negative net margin of 21.25%. The company had revenue of $183.58 million for the quarter, compared to analysts' expectations of $172.44 million. During the same period last year, the business posted ($0.36) earnings per share. The firm's quarterly revenue was up 15.6% compared to the same quarter last year. On average, analysts expect NovoCure to post ($1.21) EPS for the current fiscal year and ($0.70) EPS for the next fiscal year.

NovoCure Trading Down 0.8%

Shares of NVCR opened at $15.59 on Thursday. NovoCure has a 1 year low of $9.82 and a 1 year high of $21.45. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.89 and a quick ratio of 2.70. The firm has a fifty day moving average of $16.27 and a 200-day moving average of $15.86.

Analyst Upgrades and Downgrades

NVCR has been the topic of several recent research reports. Wedbush lifted their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Friday, July 24th. Zacks Research raised shares of NovoCure from a "strong sell" rating to a "hold" rating in a research note on Friday, July 24th. Wall Street Zen cut shares of NovoCure from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. JPMorgan Chase & Co. assumed coverage on shares of NovoCure in a research report on Monday, July 13th. They issued a "neutral" rating and a $17.00 target price for the company. Finally, HC Wainwright set a $32.00 price target on shares of NovoCure in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $21.20.

NovoCure Company Profile

NovoCure Ltd. NASDAQ: NVCR is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company's principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.